Vanguard Group Inc Surrozen, Inc. Transaction History

Vanguard Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.42 - $41.25 $176 - $17,325	420 Added 0.09%	487,698 $282,000
Q3 2022 Nov 14, 2022	BUY	$0.26 - $46.35 $3,977 - $709,108	15,299 Added 3.24%	487,278 $984,000
Q2 2022 Aug 12, 2022	BUY	$2.14 - $3.43 $2,647 - $4,242	1,237 Added 0.26%	471,979 $1.42 Million
Q1 2022 May 13, 2022	SELL	$2.2 - $6.01 $349,674 - $955,247	-158,943 Reduced 25.24%	470,742 $1.42 Million
Q4 2021 Feb 14, 2022	BUY	$6.0 - $9.92 $50,682 - $83,794	8,447 Added 1.36%	629,685 $4.06 Million
Q3 2021 Nov 12, 2021	BUY	$6.98 - $12.03 $4.34 Million - $7.47 Million	621,238 New	621,238 $4.4 Million

4.52M

Ticker SRZN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,122,900
Market Cap $430M
Description
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, a...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.